サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：コレステロール検査製品の世界市場-2023年～2030年
市場調査レポート
商品コード
1297771

コレステロール検査製品の世界市場-2023年～2030年

Global Cholesterol Testing Products Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
コレステロール検査製品の世界市場-2023年～2030年
出版日: 2023年06月15日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

コレステロール検査製品の世界市場規模は2022年に85億米ドルに達し、2030年には159億米ドルに達するなど、有利な成長が予測されています。予測期間2023-2030年のCAGRは8.3%です。

コレステロール検査製品は、血液中のコレステロール値を測定・監視するために使用される医療機器、検査キット、試薬、消耗品です。血液中のコレステロール値が高いと、心臓発作や脳卒中などの心血管疾患のリスクが高まります。ヘルスケア・プロバイダーは、心血管疾患の患者やそのリスクのある患者のコレステロール値を測定・監視するためにこれらの製品を使用します。

コレステロール検査製品の市場は、心血管疾患、脳卒中、糖尿病など、高コレステロール値に関連する健康リスクに対する意識の高まりによって牽引されています。このため、ヘルスケアプロバイダー、患者、個人によるコレステロール検査製品に対する需要が増加しています。同市場は、生活習慣病、コレステロール監視に対する意識の高まり、コレステロール検査製品の技術的進歩により成長が見込まれています。

市場力学

生活習慣病の有病率の増加

生活習慣病の有病率の増加は、コレステロール検査製品市場の成長を促進する主な要因の1つです。肥満、糖尿病、高血圧などの生活習慣病は、高コレステロール値や心血管疾患の危険因子として知られています。

例えば、世界保健機関（WHO）によると、心血管疾患、糖尿病、がんなどの非感染性疾患は、世界全体の死亡原因の約71％を占めています。運動不足、不健康な食生活、たばこの使用といった不健康な生活習慣は、これらの病気の主な危険因子です。

これらの生活習慣病の有病率が上昇を続ける中、効果的な予防、診断、管理戦略の必要性が高まっています。コレステロール検査製品は、高コレステロール値や心血管疾患を早期に発見し、管理する上で重要な役割を果たしています。このため、ヘルスケア・プロバイダーは生活習慣病の負担増に対処し、患者の予後を改善しようとするため、コレステロール検査製品に対する需要が高まっています。

製品の高コストと厳しい規制要件

市場の主な課題は、コレステロール検査製品の高コストと厳しい規制要件です。コレステロール検査製品の開発・商品化には多額の研究開発費がかかるため、最終製品の価格が高くなる可能性があります。このため、低所得国や十分なサービスを受けていない人々における利用が制限され、新興国における市場の成長が制限される可能性があります。

コレステロール検査製品に対する規制要件は、特に先進国では厳しい場合があります。これらの要件には、市販前承認、臨床試験、基準や規制の遵守などが含まれます。規制を遵守しなかった場合、罰金やその他の罰則が課される可能性があり、中小企業の市場参入や大手企業との競争を難しくしています。

COVID-19影響分析

COVID-19パンデミックはコレステロール検査製品市場に影響を与えました。パンデミックの初期段階では、ヘルスケア・システムはCOVID-19患者であふれかえり、ルーチンのコレステロール検査を含む選択的処置の減少につながっています。しかし、パンデミックが続き、ヘルスケア・システムが新たな通常状態に適応するにつれて、コレステロール検査製品に対する需要は回復し始めました。

さらに、パンデミックは遠隔医療と遠隔モニタリングの急増につながり、コレステロール検査製品に新たな機会をもたらしました。患者は現在、遠隔操作でコレステロール検査製品にアクセスし、ヘルスケア・プロバイダーとのバーチャルなコンサルテーションを受けることができるため、医療へのアクセスが改善され、COVID-19にさらされるリスクが減少しています。

ロシア・ウクライナ紛争分析

ロシアとウクライナの紛争は、ヘルスケア業界を含む世界の政治・経済情勢に大きな影響を与えています。ウクライナでは、紛争により国内避難民が大幅に増加し、ヘルスケア施設やインフラが破壊されました。

ロシアでは、紛争が貿易制限や経済制裁につながり、医療機器や供給品の入手が制限され、サプライチェーンが寸断されたため、企業がヘルスケア製品を製造・流通させることが難しくなりました。このような制限により、医療機器や消耗品の入手が制限され、サプライチェーンが混乱し、企業がヘルスケア製品を製造・販売することがより困難になっています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 生活習慣病の増加
    • 抑制要因
      • 製品の高コストと厳しい規制要件
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 製品別

  • デバイス
    • ハンドヘルドコレステロールモニタリング装置
    • 卓上型コレステロールモニタリング装置
    • 消耗品
  • 検査キット
  • その他

第8章 検査タイプ別

  • 総コレステロール
  • 低比重リポ蛋白（LDL）コレステロール
  • 高比重リポ蛋白（HDL）コレステロール
  • トリグリセリド
  • 超低比重リポ蛋白（VLDL）コレステロール

第9章 エンドユーザー別

  • 病院
  • 診断センター
  • 在宅ヘルスケア
  • 研究ラボ

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Abbott Laboratories
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • F. Hoffmann-La Roche AG
  • Siemens Healthineers
  • Danaher Corporation
  • Bio-Rad Laboratories Inc.
  • ACON Laboratories Inc.
  • Lepu Medical Technology
  • SD BIOSENSOR INC.
  • Ciga Healthcare
  • SpectraCell Laboratories Inc.

第13章 付録

目次
Product Code: MD4219

Market Overview

The Global Cholesterol Testing Products Market size reached US$ 8.5 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 15.9 billion by 2030. The market is exhibiting at a CAGR of 8.3% during the forecast period 2023-2030.

Cholesterol testing products are medical devices, test kits, reagents, and consumables used to measure and monitor cholesterol levels in the blood. High cholesterol levels in the blood can increase the risk of cardiovascular diseases such as heart attack and stroke. Healthcare providers use these products to measure and monitor cholesterol levels in patients with or at risk of cardiovascular diseases.

The market for cholesterol testing products is driven by a growing awareness of the health risks associated with high cholesterol levels, such as cardiovascular disease, stroke, and diabetes. This has led to an increased demand for cholesterol testing products by healthcare providers, patients, and individuals. The market is expected to grow due to lifestyle diseases, increased awareness of cholesterol monitoring, and technological advancements in cholesterol testing products.

Market Dynamics

Increasing Prevalence of Lifestyle Diseases

The increasing prevalence of lifestyle diseases is one of the major factors driving the growth of the cholesterol-testing products market. Lifestyle diseases such as obesity, diabetes, and hypertension are known risk factors for high cholesterol levels and cardiovascular diseases.

For instance, According to the World Health Organization, noncommunicable diseases, including cardiovascular diseases, diabetes, and cancer, account for approximately 71% of all deaths globally. Unhealthy lifestyle habits such as lack of physical activity, unhealthy diets, and tobacco use are key risk factors for these diseases.

As the prevalence of these lifestyle diseases continues to rise, there is a growing need for effective prevention, diagnosis, and management strategies. Cholesterol testing products play a crucial role in detecting and managing high cholesterol levels and cardiovascular diseases early. This has increased the demand for cholesterol testing products as healthcare providers seek to address the growing burden of lifestyle diseases and improve patient outcomes.

High Cost of the Products and Stringent Regulatory Requirements

The market's major challenges are the high cost of cholesterol testing products and stringent regulatory requirements. The development and commercialization of cholesterol testing products involves significant research and development costs, which can lead to a high price of the final products. This can limit accessibility in low-income countries and underserved populations and restrict the market growth in emerging economies.

The regulatory requirements for cholesterol testing products can be stringent, particularly in developed countries. These requirements include pre-market approval, clinical trials, and compliance with standards and regulations. Failure to comply with regulations can result in fines and other penalties, making it difficult for small and medium-sized enterprises to enter the market and compete with larger players.

COVID-19 Impact Analysis

The COVID-19 pandemic has had an impact on the cholesterol testing products market. During the early stages of the pandemic, healthcare systems were overwhelmed with COVID-19 patients, leading to a decrease in elective procedures, including routine cholesterol testing. However, as the pandemic continued and healthcare systems adapted to the new normal, the demand for cholesterol testing products began to recover.

Additionally, the pandemic has led to a surge in telemedicine and remote monitoring, which has created new opportunities for cholesterol testing products. Patients can now access cholesterol testing products remotely and receive virtual consultations with healthcare providers, improving access to care and reducing the risk of exposure to COVID-19.

Russia-Ukraine Conflict Analysis

The conflict between Russia and Ukraine has significantly impacted the global political and economic landscape, including the healthcare industry. In Ukraine, the competition has caused a significant increase in the number of internally displaced persons and destroyed healthcare facilities and infrastructure.

In Russia, the conflict has led to trade restrictions and economic sanctions, which have limited the availability of medical equipment and supplies, and disrupted supply chains, making it more difficult for companies to manufacture and distribute healthcare products. These restrictions have limited the availability of medical equipment and supplies and disrupted supply chains, making it more difficult for companies to manufacture and distribute healthcare products.

Segment Analysis

The Global Cholesterol Testing Products Market is segmented based on product, test type, end-user, and region.

The devices segment is expected to dominate the market share based on product.

The devices segment accounted for the highest market stake, accounting for approximately 52.4% of the cholesterol testing products market in 2022 due to the increasing demand for reliable and accurate devices. These devices include handheld cholesterol testing devices, point-of-care testing devices, and home cholesterol testing kits. Additionally, the growing trend of self-monitoring of cholesterol levels has increased demand for home cholesterol testing kits.

The devices segment is expected to witness significant growth in the coming years due to technological advancements, increasing demand for point-of-care testing, and the rising prevalence of lifestyle diseases such as diabetes and obesity. The development of portable and wireless cholesterol testing devices is also expected to boost the growth of this segment.

Geographical Analysis

North America will capture the highest market share due to the increased prevalence of cardiovascular diseases and demand for POCT Products.

North America has a significant market share of around 39.6% for the cholesterol testing products market due to the increased prevalence of cardiovascular diseases and the growing demand for point-of-care testing (POCT) products. Cardiovascular diseases (CVDs) are a major public health concern in North America, and high cholesterol is a significant risk factor for developing CVDs. The increasing prevalence of CVDs in the region has led to a growing demand for cholesterol testing products, including laboratory-based and POCT devices.

Furthermore, the demand for POCT products is increasing in North America, driven by the need for rapid and accurate testing results, convenience, and cost-effectiveness. POCT devices allow cholesterol testing to be performed at the point of care, such as in a doctor's office or clinic, without requiring samples to be sent to a laboratory for analysis.

In addition, the region is home to several key players in the cholesterol testing products market, who are constantly introducing new and innovative products to meet the growing demand for cholesterol testing. These companies are also investing in research and development to improve the accuracy and reliability of cholesterol testing products.

Competitive Landscape

The major global players in the market include: Abbott Laboratories, F. Hoffmann-La Roche AG, Siemens Healthineers, Danaher Corporation, Bio-Rad Laboratories Inc., ACON Laboratories Inc., Lepu Medical Technology, SD BIOSENSOR INC., Ciga Healthcare, and SpectraCell Laboratories Inc.

Why Purchase the Report?

  • To visualize the Global Cholesterol Testing Products Market segmentation based on product, test type, end-user, and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous cholesterol testing products market-level data points with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The Global Cholesterol Testing Products Market Report Would Provide Approximately 54 Tables, 46 Figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product
  • 3.2. Snippet by Test Type
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increased Prevalence of Lifestyle Diseases
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of the Products and Stringent Regulatory Requirements
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.1.2. Market Attractiveness Index, By Product
  • 7.2. Devices*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Handheld cholesterol monitoring devices
    • 7.2.4. Bench-top cholesterol monitoring devices
    • 7.2.5. Consumables
  • 7.3. Test Kits
  • 7.4. Others

8. By Test Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 8.1.2. Market Attractiveness Index, By Test Type
  • 8.2. Total Cholesterol*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Low-Density Lipoprotein (LDL) Cholesterol
  • 8.4. High-Density Lipoprotein (HDL) Cholesterol
  • 8.5. Triglycerides
  • 8.6. Very Low-Density Lipoprotein (VLDL) Cholesterol

9. By End-User

  • 9.1. Hospitals
  • 9.2. Diagnostic centers
  • 9.3. Home healthcare
  • 9.4. Research laboratories

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Abbott Laboratories*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. F. Hoffmann-La Roche AG
  • 12.3. Siemens Healthineers
  • 12.4. Danaher Corporation
  • 12.5. Bio-Rad Laboratories Inc.
  • 12.6. ACON Laboratories Inc.
  • 12.7. Lepu Medical Technology
  • 12.8. SD BIOSENSOR INC.
  • 12.9. Ciga Healthcare
  • 12.10. SpectraCell Laboratories Inc.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us